Evidence map›Paper›PMID 39833682›Full record

ArticleClinical proteomics2025

ARTN and CCL23 predicted chemosensitivity in acute myeloid leukemia: an Olink

Ting-Shuan Wu, Tzu-Hung Hsiao, Chung-Hsing Chen, Hsin-Ni Li, Miao-Neng Hung, Pei-Pei Jhan, Jia-Rung Tsai, Chieh-Lin Jerry Teng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical proteomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ting-Shuan Wu *Department of Biomedical Sciences, Chung Shan Medical University, No. 110, Sect. 1, Jiangou North Rd, Taichung, 40201, Taiwan.
Tzu-Hung Hsiao *Department of Medical Research, Taichung Veterans General Hospital, 1650 Taiwan Boulevard Sect. 4, Taichung, 40705, Taiwan.
Chung-Hsing ChenDepartment of Mathematics, University of Taipei, No. 1 Ai-Guo West Rd, Taipei, 100234, Taiwan.
Hsin-Ni LiDepartment of Pathology and Laboratory Medicine, Taichung Veterans General Hospital, 1650 Taiwan Boulevard Sect. 4, Taichung, 40705, Taiwan.
Miao-Neng HungDepartment of Biomedical Sciences, Chung Shan Medical University, No. 110, Sect. 1, Jiangou North Rd, Taichung, 40201, Taiwan.
Pei-Pei JhanDepartment of Medical Research, Taichung Veterans General Hospital, 1650 Taiwan Boulevard Sect. 4, Taichung, 40705, Taiwan.
Jia-Rung TsaiDivision of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, 1650 Taiwan Boulevard Sect. 4, Taichung, 40705, Taiwan.
Chieh-Lin Jerry TengDivision of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, 1650 Taiwan Boulevard Sect. 4, Taichung, 40705, Taiwan. drteng@vghtc.gov.tw.

Funding

National Science and Technology Council NSTCNSTC 112-2314-B-005-011Taichung Veterans General Hospital TCVGH-1133701D
6 · The paper itself

Abstract

backgroundThe standard "7 + 3" induction results in 30% of de novo acute myeloid leukemia (AML) patients not achieving complete remission (CR). We aimed to utilize the Olink

methodsThis prospective study included 43 untreated AML patients, stratified into CR (n = 29) and non-CR (n = 14) groups based on their response to "7 + 3" induction therapy. We employed the Olink

resultsProteomic analysis demonstrated that the CR group exhibited significantly higher bone marrow plasma levels of ARTN and CCL23 than did the non-CR group. Immunohistochemical staining confirmed a higher proportion of tissue samples with intense staining for ARTN (25.40% vs. 7.05%, p = 0.013) and CCL23 (24.14% vs. 14.29%, p = 0.039) in the CR group. These findings were corroborated by bulk-RNA-seq, which indicated significantly elevated mRNA expression levels of ARTN (1.93 vs. -0.09; p = 0.003) and CCL23 (1.50 vs. 0.12; p = 0.021) in the CR group. The Human Protein Atlas provided external support for our findings.

conclusionsThe results suggest that ARTN and CCL23 may serve as biomarkers for predicting responsiveness to the "7 + 3" induction in untreated AML. Using an enzyme-linked immunosorbent assay to identify the roles of ARTN and CCL23 in predicting AML chemosensitivity may enhance clinical applicability in the future.

Indexed as

Acute myeloid leukemiaARTNCCL23ChemosensitivityOlink®Proteomics

Identifiers

PMID39833682
PMCPMC11749431

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.